| By Rudy Sims | Article Rating: |
|
| June 26, 2009 12:15 AM EDT | Reads: |
1,395 |
I was very sad to hear about Michael Jackson's death I grew up with his music I'm currently 31 years old and despite my disability I did my best as a young child to imitate his dance moves when I was dancing to his music whether it was in my wheelchair or on my knees his music helped me forget about my disability for that time.
Here is a round up of several new stories about Michael Jackson's health and sudden death
Michael Jackson Dies of Reported Cardiac Arrest - webmd.com
Michael Jackson had history of health problems - CNN
Michael Jackson's Mysterious Medical Past TIME
michael jackson health history Google Search
Published June 26, 2009 Reads 1,395
Copyright © 2009 Ulitzer, Inc. — All Rights Reserved.
Syndicated stories and blog feeds, all rights reserved by the author.
Related Stories
More Stories By Rudy Sims
I am currently 31 years old I have a disability called cerebral palsy and I am in a wheelchair I was born with cerebral palsy and I have had three operations to try and manage it. My last operation went badly and I experienced very severe postoperative chronic pain for 10 years. I am doing great now and I want to help others with disabilities and chronic illnesses cope effectively with their conditions.
- New Treatment for Patients with Bipolar I Disorder
- UCB Announces Start of the EXXELERATE™ Clinical Study in Rheumatoid Arthritis
- Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth Quarter and Full-Year 2011
- MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis
- Merck Serono Receives European Approval to Expand Use of Rebif® in Patients with Early Multiple Sclerosis
- Muhammad Ali's 70th Birthday Celebration From Las Vegas at the MGM Grand Garden Arena
- Kessler Foundation Awards $425,000 Grant to University of Hawaii Disability Employment Initiative
- New Breast Cancer Treatment Available in Italy
- Nobelpharma and Eisai Announce Japan Launch of Anticonvulsant Agent Fostoin 750 mg for Injection
- Assistant Secretary Martinez Meets With Disability Employment Leaders at Kessler Foundation
- FDA Permits Marketing of First Test For Risk of Rare Brain Infection in Some People Treated With Tysabri
- Kessler Foundation Awards $250,000 Grant to Boston Disability Employment Initiative
- New Treatment for Patients with Bipolar I Disorder
- UCB Announces Start of the EXXELERATE™ Clinical Study in Rheumatoid Arthritis
- Abbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in Fourth Quarter and Full-Year 2011
- MorphoSys Initiates Phase 1b Clinical Trial with MOR103 in Patients with Multiple Sclerosis
- Priory Group: Results for the Three and Nine Months Ended 30 September 2011
- Merck Serono and Ablynx Expand Their Partnership Into Osteoarthritis
- Experts Call for More Innovative Public Health Campaigns to Improve Folate Supplementation in Women Planning a Pregnancy, as Prevalence of Neural Tube Defects in Europe Remains Largely Undiminished in a Decade[1]
- New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response
- Merck Serono Receives European Approval to Expand Use of Rebif® in Patients with Early Multiple Sclerosis
- New Data From REALISTIC Study Showed Cimzia® (certolizumab pegol) Provided Rapid and Sustained Efficacy, Over 28 Weeks, in a Broad Population of Patients With Moderate to Severe Rheumatoid Arthritis (RA) Including Those Who Discontinued Prior Anti-TNF The
- New Data on Patient-Reported Improvements in Quality of Life Measures and Other Clinical Responses in Moderate to Severe Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol) Highlighted at American College of Rheumatology Meeting
- Muhammad Ali's 70th Birthday Celebration From Las Vegas at the MGM Grand Garden Arena
- Contrary Opinion: CRM is a Hoax
- 22nd Annual ROTH OC Growth Stock Conference Presenter Profiles
- Merck Serono a reçu une lettre de réponse de la FDA à sa demande d'enregistrement de 'Cladribine Comprimés'
- An Introduction to My Health 2.0 Blog
- Surplus PC Power Yields Faster Cancer Research
- Inclusion Has Come A Long Way..
- Merck Serono: Mise à jour concernant les procédures d'enregistrement de 'Cladribine Comprimés'
- ADDING and REPLACING 22nd Annual ROTH OC Growth Stock Conference Presenter Profiles
- Merck Serono: Regulatory Update on Cladribine Tablets
- Merck Serono Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
- About Disability Resource Exchange Social Network
- Merck Serono erhält "Complete Response Letter" der FDA zum Zulassungsantrag für Cladribin-Tabletten
















Ulitzer content is offered under Creative Commons "Attribution Non-Commercial No Derivatives" License.
For any reuse or distribution, you must make clear to others the license terms of this work.
The best way to do this is with a link to this web page.
Any of the above conditions can be waived if you get written permission from Ulitzer, Inc., the copyright holder.
Nothing in this license impairs or restricts the author's moral rights.